Hematologic Oncology | Specialty

Transfusion Dependence in MDS: The Risk for Iron Overload

March 8th 2016

Choosing Lenalidomide vs ESAs in Del 5q MDS

March 8th 2016

Factors to Consider in the Initial Treatment of MDS

March 8th 2016

Classification and Prognosis in MDS

March 8th 2016

Understanding MDS Disease Characteristics and Progression

March 8th 2016

FDA Approval Sought for Blinatumomab in Pediatric Acute Lymphoblastic Leukemia

March 3rd 2016

A supplemental biologics license application has been submitted to the FDA to expand the approval of blinatumomab (Blincyto) to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

FDA Grants Midostaurin Breakthrough Designation for AML

February 19th 2016

The FDA has granted midostaurin a breakthrough therapy designation as a potential treatment for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia.

Bringing Epigenetic Therapies From Bench to Bedside

February 15th 2016

Epigenetic therapy has emerged as a novel approach, not necessarily by killing cancer cells, but perhaps by altering the network of chemical changes that affect the DNA/chromatin within cancer cells.

FDA Approval in Liposarcoma, Breakthrough Designations in mCRPC and AML, and More

February 5th 2016

Dr. Nguyen on ABL001 in Patients With CML

February 5th 2016

Marie Huong Nguyen, MD, assistant professor, Hematology and Oncology, University of Michigan Health System, discusses the safety and efficacy of ABL001 as a potential treatment for patients with chronic myeloid leukemia.

Blinatumomab Improves Survival in Acute Lymphoblastic Leukemia

February 5th 2016

The phase III TOWER study has been halted after an independent panel determined that blinatumomab (Blincyto) improved overall survival versus standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Dr. Maciejewski on Impact of Eltrombopag on Expansion of Clones in Refractory Aplastic Anemia

February 1st 2016

Jaroslaw P. Maciejewski, MD, PhD, chair, Department of Translational Hematology and Oncology Research, Cleveland Clinic, discusses the impact of eltrombopag on an expansion of clones with somatic mutations in patients with refractory aplastic anemia.

Dr. Hamilton on Prognostic Impact of Molecular Mutations in AML and MDS on HCT Outcomes

January 29th 2016

Betty Hamilton, MD, associate staff physician, Department of Hematologic Oncology and Blood Disorders and Blood and Marrow Transplant Program, discusses the prognostic impact of molecular mutations in acute myeloid leukemia and myelodysplastic syndromes on allogeneic hematopoietic cell transplant outcomes and the adverse impact of TET2 mutations.

Experts Emphasize Importance of Preventing Progression in CML

January 29th 2016

Early diagnosis and early commencement of the most effective treatment available are essential in managing patients with chronic myeloid leukemia, particularly since therapeutic options have expanded and testing technology has advanced.

FDA Grants Venetoclax Breakthrough Designation in AML

January 28th 2016

Venetoclax has received an FDA breakthrough therapy designation for use in combination with hypomethylating agents in treatment-naïve patients with acute myeloid leukemia who are not eligible for standard high-dose induction treatment.

Dr. Park on Alisertib in Myc-Overexpressing Lymphoma Cells

January 28th 2016

Steven I. Park, MD, director, Lymphoma Program, associate professor of Medicine, Leukemia, Lymphoma, and Myeloma Program, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Clinical Research, discusses how alisertib induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma cells.

Dr. Sekeres on Combination Therapies With Azacitidine in CMML and MDS

January 21st 2016

Mikkael A. Sekeres, MD, MS, professor of Medicine, director, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, discusses a study examining azacitidine combined with lenalidomide or with vorinostat versus azacitidine monotherapy in higher-risk patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Dr. Mukherjee on Radioactive Iodine Treatment of Thyroid Cancer and Risk of MDS

January 20th 2016

Sudipto Mukherjee, MD, associate staff, Department of Hematology and Oncology, Cleveland Clinic, discusses a study examining the association between radioactive iodine treatment of thyroid cancer and the risk for developing myelodysplastic syndromes.

Dr. Mauro on Selecting Therapies for Patients With CML

January 15th 2016

Michael J. Mauro, MD, hematologist, leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses how to best select therapies for patients with chronic myeloid leukemia.

Closing Thoughts on Managing Chronic Myeloid Leukemia

January 14th 2016